Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Business
INVESTOR'S BUSINESS DAILY

Cencora Earns Composite Rating Upgrade

Cencora saw its IBD SmartSelect Composite Rating jump to 96 Monday, up from 94 the day before.

The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength. Winning stocks often have a 95 or higher rating in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.

Cencora is currently forming a flat base, with a 262.25 buy point. Look for the stock to break out in volume at least 40% higher than normal. But note that it's a later-stage base, and such bases are more prone to failure.

Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets

The stock earns a 92 EPS Rating, meaning its recent quarterly and annual earnings growth tops 92% of all stocks.

Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.

The company posted a 14% earnings gain for Q1. Top line growth fell to 13%, down from 15% in the prior quarter.

Cencora earns the No. 1 rank among its peers in the Medical-Wholesale Drugs industry group. McKesson and Cardinal Health are also among the group's highest-rated stocks.

This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.